




PATENT
Confirmation No. 7839
Atty. Docket No. PP-1512.101

#9

I hereby certify that this paper(s) is/are being deposited with in the United States Postal Service "Express Mail Post Office to Addressee", No. EL 738442112 US, service under CFR 1.10 on the date indicated and addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231-0001, on February 3, 2003.


Nancy L. Swanson

2/3/03
Date

RECEIVED
FEB 10 2003
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Lewis T. Williams et al.
Serial No.: 09/762,693 Group Art: 1636
Filed: July 3, 2001 Examiner: Q. Nguyen
For: ENGINEERED ANTIGEN-PRESENTING CELLS EXPRESSED AN
ARRAY OF ANTIGENS AND USES THEREOF

RESPONSE UNDER 37 C.F.R. § 1.111

Sir:

Applicant submits this response to the Office Action dated October 1, 2002, Paper No. 8. Please extend the period of time for response for three months, to expire on February 3, 2003. Enclosed are a Petition for an Extension of Time and the requisite fee.

Election/Restrictions

Group Restriction:

Applicant hereby elects Group III, claims 17-29, 32-35, 77 and 39, drawn to a method for producing an antigen-presenting cell that presents an array of antigens, an antigen presenting cell produced by the same method, and methods for activating T cells, for killing a target cell *in vivo*, and for treating cancer using the same antigen presenting cell.

02/06/2003 SDENBOB1 00000028 09762693

1

01 FC:1253

930.00 OP

Species Restriction:

In the Office Action, the Examiner also required the Applicant to elect for Group III, regarding claims 17-27 28, 30 32-35, a specifically named species. Applicant elects from claim 18, dendritic cell as the antigen-presenting cell; from claim 24, neomycin resistance as the selectable marker; from claims 25 and 26, cancer cell as the target cell; and from claim 35; and IL-2 as the immunomodulatory cofactor.

Favorable consideration and allowance of the elected claims is respectfully requested.

The Assistant Commissioner is hereby authorized to charge any additional fees (or credit any overpayment) associated with this communication and which may be required under 37 CFR 1.16 and 1.17 to Deposit Account No. 03-1664. This, however, is not authorization to pay the issue fee.

Respectfully submitted,



Charlene A. Launer
Registration No. 33,035
Attorney for Applicant

Date: 2/3/03

CHIRON CORPORATION
Intellectual Property
4560 Horton Street
Emeryville, CA 94608-2916
Telephone: (510) 923-2718
Facsimile: (510) 655-3542